Pediatrix Medical Group, Inc. MD

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 46.7% gain over the past six months, beating the S&P 500 by 25.6 percentage points.

Pediatrix Medical Group (MD) has drawn fresh attention after trading around a recent close of US$25.93. Investors are weighing this level against the company’s longer term return record and its current healthcare services footprint. Recent trading has been choppy for Pediatrix Medical Group, with a 1-day share price return of 1.73% offsetting some of the pressure from a 7-day share price return that slipped 3.64%. At the same time, the year-to-date share price return of 21.79% and a 1-year...

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

On August 4, Pediatrix Medical Group (NYSE:MD) reported second-quarter results that look strong on the surface. Adjusted earnings per share jumped to $0.63 from $0.53, and net revenue grew to $487.8 million. But look past the headline numbers, and the growth is coming largely from pricing and a shrinking share count, not from more patients […]

Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Figure 1 Abitibi Projects Figure 2 Abitibi-Detour Trend Projects Figure 3 Casault Project MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Midland Exploration Inc. (“Midland”) (TSX-V: MD), in partnership with Wallbridge Mining Company Ltd (“Wallbridge”), is pleased to announce that field crews and a diamond drill rig are being mobilized to the Casault gold property in preparation for the commencement of a 3,000 metre diamond drilling campaign in this week. Highlights: Drilling program totalling appro

Looking back on healthcare providers & services stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Pediatrix Medical Group (NYSE:MD) and its peers.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Pediatrix Medical Group’s second quarter was marked by revenue growth exceeding Wall Street’s expectations, but the market responded negatively, reflecting concerns about profitability and underlying operational trends. Management attributed the top-line gains to improved revenue cycle management collections, a favorable payer mix, and rising patient acuity, while acknowledging a modest decline in same-unit patient volumes, particularly in neonatology. CEO Mark Ordan noted, “Same unit revenue wa

Why Pediatrix Medical Group’s latest earnings matter for investors Pediatrix Medical Group (MD) recently reported second quarter and first half 2026 results, with higher sales, net income, and earnings per share from continuing operations compared with the same periods a year earlier. See our latest analysis for Pediatrix Medical Group. Pediatrix Medical Group’s earnings update comes after a strong run in the stock, with a 90 day share price return of 15.88% and a year to date share price...

Pediatrix Medical Group, Inc. reported past second-quarter 2026 results with sales of US$487.78 million and net income of US$39.84 million, both higher than a year earlier, alongside slightly improved basic and diluted earnings per share from continuing operations. Over the first half of 2026, the company’s higher sales of US$963.98 million and net income of US$69.42 million indicate that recent operational and cost initiatives are feeding through into stronger earnings per share from...